darifenacin and Intestinal-Obstruction

Darifenacin (Enablex) and solifenacin (VESIcare) are 2 new oral anticholinergics available for once-daily symptomatic treatment of overactive bladder. Overactive bladder is a common condition in older patients. The 5 drugs currently approved for treatment are modestly effective but also cause anticholinergic adverse effects such as dry mouth and constipation and can cause confusion in the elderly. In some experimental studies, the new drugs particularly target bladder receptors, but the clinical significance of these findings is unknown.

Topics: Benzofurans; Drug Interactions; Humans; Intestinal Obstruction; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines; Urinary Incontinence; Xerostomia